Shopping Cart

Remove All

Your shopping cart is currently empty

Osilodrostat

Select Batch

Purity:99.12%

Resource Download

COA HPLC HNMR LCMS

Osilodrostat

Catalog No. T4277Cas No. 928134-65-0

Osilodrostat (LCI699) (LCI699) is an effective inhibitor of human 11β-hydroxylase (IC50: 2.5 nM) and aldosterone synthase (IC50: 0.7 nM).

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

Pack Size	Price	Availability
1 mg	$43	In Stock
2 mg	$61	In Stock
5 mg	$85	In Stock
10 mg	$126	In Stock
25 mg	$207	In Stock
50 mg	$401	In Stock
1 mL x 10 mM (in DMSO)	$74	In Stock

Bulk & Custom

Add to Cart

Questions

Related Compound Libraries of "Osilodrostat"

Product Introduction

Bioactivity

Description	Osilodrostat (LCI699) (LCI699) is an effective inhibitor of human 11β-hydroxylase (IC50: 2.5 nM) and aldosterone synthase (IC50: 0.7 nM).
In vivo	Osilodrostat and pasireotide monotherapies can significantly affect in the histology and mean weights of the pituitary and adrenal glands, liver, and ovary/oviduct. Osilodrostat is associated with adrenocortical hypertrophy and hepatocellular hypertrophy. The combination of Osilodrostat with pasireotide ameliorates the liver and adrenal gland changes observed with monotherapy and does not exacerbate any target organ changes. Cmax and AUC(0–24h) of Osilodrostat and pasireotide increase in an approximately dose-proportional manner. Osilodrostat treatment reduces urinary free cortisol in patients with Cushing's disease; 78.9% has normal urinary free cortisol at week 22.
Animal Research	Sixty male and 60 female rats are randomized into single-sex groups to receive daily doses of pasireotide (0.3 mg/kg/day, s.c.), osilodrostat (20 mg/kg/day, p.o.), osilodrostat/pasireotide in combination (low dose, 1.5/0.03 mg/kg/day; mid-dose, 5/0.1 mg/kg/day; or high dose, 20/0.3 mg/kg/day), or vehicle for 13 weeks.
Alias	LCI699

Chemical Properties

Molecular Weight	227.24
Formula	C13H10FN3
Cas No.	928134-65-0

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Solubility Information

DMSO: 50 mg/mL (220.03 mM)

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	4.4006 mL	22.0032 mL	44.0063 mL	220.0317 mL
5 mM	0.8801 mL	4.4006 mL	8.8013 mL	44.0063 mL
10 mM	0.4401 mL	2.2003 mL	4.4006 mL	22.0032 mL
20 mM	0.2200 mL	1.1002 mL	2.2003 mL	11.0016 mL
50 mM	0.0880 mL	0.4401 mL	0.8801 mL	4.4006 mL
100 mM	0.0440 mL	0.2200 mL	0.4401 mL	2.2003 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:

For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments

A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent

DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。

Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO TargetMol | reagent

(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.

Preparation method for in vivo formula: Take 50 μL DMSO TargetMol | reagent

main solution, add 300 μLPEG300 TargetMol | reagent

mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O TargetMol | reagent

mix well and clarify

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc